GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » Institutional Ownership

Kadimastem (XTAE:KDST) Institutional Ownership : 0.11% (As of Jun. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kadimastem Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kadimastem's institutional ownership is 0.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kadimastem's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kadimastem's Float Percentage Of Total Shares Outstanding is 0.00%.


Kadimastem Institutional Ownership Historical Data

The historical data trend for Kadimastem's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem Institutional Ownership Chart

Kadimastem Historical Data

The historical data trend for Kadimastem can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.26 0.26 0.26 0.26 0.26 0.26 0.11 0.11 0.11 0.11

Kadimastem Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Kadimastem (XTAE:KDST) Business Description

Traded in Other Exchanges
Address
Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR
Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem (XTAE:KDST) Headlines

No Headlines